Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2008

View Archived Issues

Novel therapeutic agents for neurologic disorders reported in recent patents

Results from animal studies indicate potential use for AMN-082 in treating inflammatory pain

Allergan acquires acne treatment Aczone from QLT for USD 150 million

Rottapharm's new analgesic CR-4056 modulates neurotransmitter release in vitro

New anticancer agents described in recent patent literature

Recent patents disclose new treatment options for metabolic disorders

Motesanib diphosphate induces partial responses in patients with thyroid cancer

Glenmark's neuropathic pain candidate, GRC-10693, to enter phase I trials

Jerini receives European approval for Firazyr for hereditary angioedema

Novo Nordisk files NDA for liraglutide in Japan

OSI initiates phase I OSI-027 in patients with advanced solid tumors or lymphoma

Phase II RX-3341 trial initiated in complicated skin and skin structure infections

Infinity discontinues enrollment in phase II IPI-504 study in prostate cancer

Theravance presents positive phase II results for GSK-961081 in COPD

Sigma-Tau's 5-HT6 receptor ligand shows antidepressant-like activity in vivo

DiaMedica meets primary endpoint from phase II trial of DM-83 in type 2 diabetes

Perlegen out-licenses 6 patented complementary technologies for genetic diagnostics

Pro-Pharmaceuticals requests pre-IND meeting with FDA to define regimen for EZ-646

AMT enters collaboration with St. Jude Children's Hospital for hemophilia B gene therapy

Health Canada approves SyntheMed's Repel-CV for open heart surgery in pediatric patients

FDA approves Roxane's NDA for morphine sulfate tablets and oral solution

Oramed completes equity financing of USD 5 million through private placement

Collegium closes USD 20 million series D equity financing

Actonel and Benet receive additional indication approval in Japan for Paget's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...